International Journal of Hematology and Oncology
2024, Vol 34, Num 4 Page(s): 213-219
| Back | Table of Contents | PDF | Mail to Author | |
Long-Term Survival and Disease-Free Rates in Locoregional Anal Squamous Cell Carcinoma: An Institutional Experience
Nadiye SEVER1, Sedat YILDIRIM2, Hacer Sahika YILDIZ2, Sermin DINC SONUSEN3, Abdussamet CELEBI1, Nargiz MAJIDOVA1, Alper YASAR2, Erkam KOCAASLAN1, Pinar EREL1, Yesim AGYOL1, Ali Kaan GUREN1, Selver ISIK1, Ozlem ERCELEP1, Rukiye ARIKAN1, Ibrahim Vedat BAYOGLU1, Murat SARI1, Osman KOSTEK1
1Marmara University, Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology
2Kartal Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology
3Okmeydani Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology
Keywords: Locoregional Anal SCC- Chemoradiotherapy -Long Term Survival-Disease Free Survival-Treatment Outcomes
In this study, we aimed that the analysis of demographic characteristics, clinical parameters, treatment modalities, and chemotherapy regimens in patients with anal squamous cell carcinoma (SCC) sheds light on disease management. We scanned the electronic database and patient files for patients with anal SCC who presented to our medical oncology outpatient clinic and treated between January 1, 2002 and June 1, 2022. The study included 44 patients whose information was available. The study included a total of 44 patients. The median age was 59.0 (IQR 49.5-68.0) years. The female to male ratio was approximately 1.93, and 93.6% had an Eastern Cooperative Oncology Group (ECOG) performance score of 0-1. Approximately, half of the patients had a history of recent or past smoking. The tumor location was predominantly (89.4%) anal canal and the tumor stages were 10.6%, 59.6% and 29.8% for stage I, stage II and stage III, respectively. The mean follow-up was 50.0 (IQR 29.3-70.6) months. 3rd- and 5th-year -disease free survival (DFS) rates were 82.8% and 77.9%, respectively. During the last follow-up, 76.9% of patients with anal cancer were alive and 75% of patients were disease-free. There was no statistically significant difference in the survival analysis and DFS times according to age, gender and stage. The clinical and demographic characteristics, treatment modalities, and chemotherapy regimens in patients with anal SCC provide valuable insights into disease management. The diverse tumor staging and widespread use of definitive chemoradiotherapy administered concurrently with mitomycin plus fluorouracil underscore the complexity of treatment decisions for patients with anal SCC.
Nadiye SEVER1, Sedat YILDIRIM2, Hacer Sahika YILDIZ2, Sermin DINC SONUSEN3, Abdussamet CELEBI1, Nargiz MAJIDOVA1, Alper YASAR2, Erkam KOCAASLAN1, Pinar EREL1, Yesim AGYOL1, Ali Kaan GUREN1, Selver ISIK1, Ozlem ERCELEP1, Rukiye ARIKAN1, Ibrahim Vedat BAYOGLU1, Murat SARI1, Osman KOSTEK1
1Marmara University, Faculty of Medicine, Department of Internal Medicine, Division of Medical Oncology
2Kartal Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology
3Okmeydani Training and Research Hospital, Department of Internal Medicine, Division of Medical Oncology
Keywords: Locoregional Anal SCC- Chemoradiotherapy -Long Term Survival-Disease Free Survival-Treatment Outcomes
In this study, we aimed that the analysis of demographic characteristics, clinical parameters, treatment modalities, and chemotherapy regimens in patients with anal squamous cell carcinoma (SCC) sheds light on disease management. We scanned the electronic database and patient files for patients with anal SCC who presented to our medical oncology outpatient clinic and treated between January 1, 2002 and June 1, 2022. The study included 44 patients whose information was available. The study included a total of 44 patients. The median age was 59.0 (IQR 49.5-68.0) years. The female to male ratio was approximately 1.93, and 93.6% had an Eastern Cooperative Oncology Group (ECOG) performance score of 0-1. Approximately, half of the patients had a history of recent or past smoking. The tumor location was predominantly (89.4%) anal canal and the tumor stages were 10.6%, 59.6% and 29.8% for stage I, stage II and stage III, respectively. The mean follow-up was 50.0 (IQR 29.3-70.6) months. 3rd- and 5th-year -disease free survival (DFS) rates were 82.8% and 77.9%, respectively. During the last follow-up, 76.9% of patients with anal cancer were alive and 75% of patients were disease-free. There was no statistically significant difference in the survival analysis and DFS times according to age, gender and stage. The clinical and demographic characteristics, treatment modalities, and chemotherapy regimens in patients with anal SCC provide valuable insights into disease management. The diverse tumor staging and widespread use of definitive chemoradiotherapy administered concurrently with mitomycin plus fluorouracil underscore the complexity of treatment decisions for patients with anal SCC.
| Back | Table of Contents | PDF | Mail to Author | |